Teclistamab for patients with heavily pretreated relapsed/refractory multiple myeloma and renal impairment
Abstract: Outcomes of bispecific antibodies in patients with renal impairment (RI) are not well characterized, given the exclusion of these patients from clinical trials. Herein, we evaluated patients with relapsed/refractory multiple myeloma and RI treated with standard-of-care teclistamab. RI was...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-07-01
|
| Series: | Blood Advances |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2473952925002113 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850106341493833728 |
|---|---|
| author | Danai Dima Aimaz Afrough Utkarsh Goel Ariel F. Grajales-Cruz Jack Khouri Kelley Julian Oren Pasvolsky Rahul Banerjee Beatrice Razzo Christopher J. Ferreri Mariola A. Vazquez-Martinez James A. Davis Aishwarya Sannareddy Omar Castaneda Shahzad Raza Andrew J. Portuguese Mahmoud R. Gaballa Masooma S. Rana Alex Lieberman-Cribbin Shaun DeJarnette Rebecca Gonzalez Anna Chen Megan M. Herr Lekha Mikkilineni Hitomi Hosoya Evguenia Ouchveridze Gurbakhash Kaur Adriana Rossi Leyla Shune Faiz Anwer Yi Lin Shambavi Richard Douglas W. Sborov Rachid C. Baz Alfred L. Garfall Hans C. Lee Larry D. Anderson, Jr. Andrew J. Cowan Krina K. Patel Peter M. Voorhees Surbhi Sidana Doris K. Hansen Shebli Atrash Sandra P. Susanibar-Adaniya |
| author_facet | Danai Dima Aimaz Afrough Utkarsh Goel Ariel F. Grajales-Cruz Jack Khouri Kelley Julian Oren Pasvolsky Rahul Banerjee Beatrice Razzo Christopher J. Ferreri Mariola A. Vazquez-Martinez James A. Davis Aishwarya Sannareddy Omar Castaneda Shahzad Raza Andrew J. Portuguese Mahmoud R. Gaballa Masooma S. Rana Alex Lieberman-Cribbin Shaun DeJarnette Rebecca Gonzalez Anna Chen Megan M. Herr Lekha Mikkilineni Hitomi Hosoya Evguenia Ouchveridze Gurbakhash Kaur Adriana Rossi Leyla Shune Faiz Anwer Yi Lin Shambavi Richard Douglas W. Sborov Rachid C. Baz Alfred L. Garfall Hans C. Lee Larry D. Anderson, Jr. Andrew J. Cowan Krina K. Patel Peter M. Voorhees Surbhi Sidana Doris K. Hansen Shebli Atrash Sandra P. Susanibar-Adaniya |
| author_sort | Danai Dima |
| collection | DOAJ |
| description | Abstract: Outcomes of bispecific antibodies in patients with renal impairment (RI) are not well characterized, given the exclusion of these patients from clinical trials. Herein, we evaluated patients with relapsed/refractory multiple myeloma and RI treated with standard-of-care teclistamab. RI was defined as creatinine clearance (CrCl) <40 mL/min. CrCl <30 mL/min or dialysis dependence was defined as severe RI. Of the 384 included patients, 81 (21%) had RI, including 45 (18%) with severe RI, and 18 (5%) on dialysis. Patients with RI were more likely to be older (median age, 71 vs 67 years; P = .002) and have a higher median number of previous lines of therapy (7 vs 6; P = .04). Rates and severity of cytokine release syndrome (51% vs 59%; grade ≥3: 1.2% vs 1%) and immune effector cell–associated neurotoxicity syndrome (16% vs 13%; grade ≥3: 2.5% vs 2.6%) were similar in patients with and without RI, respectively. Patients with RI had higher baseline and day 30 post-teclistamab grade ≥3 anemia and grade ≥3 thrombocytopenia. Renal function did not worsen after teclistamab initiation in most patients with RI outside of the context of disease progression. Overall response rate (52% vs 56%; P = .61) and survival outcomes (median progression-free survival, 4.6 vs 6.5 months; P = .62) were comparable in patients with and without RI, respectively, after a median follow-up of 9.9 months. No differences in overall survival or non-relapse mortality were noted. Our findings suggest that treatment with teclistamab is feasible in patients with RI, including those on dialysis, with a similar safety and efficacy profile to patients without RI. |
| format | Article |
| id | doaj-art-a0332191219941c5935d1f94fbed9dff |
| institution | OA Journals |
| issn | 2473-9529 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Blood Advances |
| spelling | doaj-art-a0332191219941c5935d1f94fbed9dff2025-08-20T02:38:51ZengElsevierBlood Advances2473-95292025-07-019143408341710.1182/bloodadvances.2025016059Teclistamab for patients with heavily pretreated relapsed/refractory multiple myeloma and renal impairmentDanai Dima0Aimaz Afrough1Utkarsh Goel2Ariel F. Grajales-Cruz3Jack Khouri4Kelley Julian5Oren Pasvolsky6Rahul Banerjee7Beatrice Razzo8Christopher J. Ferreri9Mariola A. Vazquez-Martinez10James A. Davis11Aishwarya Sannareddy12Omar Castaneda13Shahzad Raza14Andrew J. Portuguese15Mahmoud R. Gaballa16Masooma S. Rana17Alex Lieberman-Cribbin18Shaun DeJarnette19Rebecca Gonzalez20Anna Chen21Megan M. Herr22Lekha Mikkilineni23Hitomi Hosoya24Evguenia Ouchveridze25Gurbakhash Kaur26Adriana Rossi27Leyla Shune28Faiz Anwer29Yi Lin30Shambavi Richard31Douglas W. Sborov32Rachid C. Baz33Alfred L. Garfall34Hans C. Lee35Larry D. Anderson, Jr.36Andrew J. Cowan37Krina K. Patel38Peter M. Voorhees39Surbhi Sidana40Doris K. Hansen41Shebli Atrash42Sandra P. Susanibar-Adaniya43Division of Hematology-Oncology, Fred Hutch Cancer Center, University of Washington, Seattle, WA; Department of Hematology-Oncology, Cleveland Clinic Taussig Cancer Center, Cleveland, OH; Correspondence: Danai Dima, Fred Hutchinson Cancer Center, 1100 Fairview Ave N, Seattle, WA 98109;Myeloma, Waldenstrom’s, and Amyloidosis Program, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TXDivision of Hematology-Oncology, Fred Hutch Cancer Center, University of Washington, Seattle, WADepartment of Blood and Marrow Transplantation and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FLDivision of Hematology-Oncology, Fred Hutch Cancer Center, University of Washington, Seattle, WADivision of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, The University of Utah, Salt Lake City, UTDepartment of Lymphoma/Myeloma, MD Anderson Cancer Center, Houston, TXDivision of Hematology-Oncology, Fred Hutch Cancer Center, University of Washington, Seattle, WADepartment of Hematology-Oncology, University of Pennsylvania, Philadelphia, PADepartment of Hematologic Oncology and Blood Disorders, Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, NCDepartment of Blood and Marrow Transplantation and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FLDepartment of Pharmacy, University of South Carolina, Charleston, SCMyeloma, Waldenstrom’s, and Amyloidosis Program, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TXDepartment of Blood and Marrow Transplantation and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FLDepartment of Hematology-Oncology, Cleveland Clinic Taussig Cancer Center, Cleveland, OHDivision of Hematology-Oncology, Fred Hutch Cancer Center, University of Washington, Seattle, WADepartment of Lymphoma/Myeloma, MD Anderson Cancer Center, Houston, TXDivision of Bone Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, CADivision of Hematology-Oncology, Icahn School of Medicine at Mount Sinai, New York, NYDepartment of Hematology-Oncology, University of Kansas Medical Center, Kasnas City, KSDepartment of Blood and Marrow Transplantation and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FLDepartment of Hematology-Oncology, University of Pennsylvania, Philadelphia, PADepartment of Medicine, Transplant and Cellular Therapy Program, Roswell Park Comprehensive Cancer Center, Buffalo, NYDivision of Bone Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, CADivision of Bone Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, CADepartment of Hematology-Oncology, University of Kansas Medical Center, Kasnas City, KSMyeloma, Waldenstrom’s, and Amyloidosis Program, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TXDivision of Hematology-Oncology, Icahn School of Medicine at Mount Sinai, New York, NYDepartment of Hematology-Oncology, University of Kansas Medical Center, Kasnas City, KSDepartment of Hematology-Oncology, Cleveland Clinic Taussig Cancer Center, Cleveland, OHDivision of Hematology, Mayo Clinic, Rochester, MNDivision of Hematology-Oncology, Icahn School of Medicine at Mount Sinai, New York, NYDivision of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, The University of Utah, Salt Lake City, UTDepartment of Blood and Marrow Transplantation and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FLDepartment of Hematology-Oncology, University of Pennsylvania, Philadelphia, PADepartment of Lymphoma/Myeloma, MD Anderson Cancer Center, Houston, TXMyeloma, Waldenstrom’s, and Amyloidosis Program, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TXDivision of Hematology-Oncology, Fred Hutch Cancer Center, University of Washington, Seattle, WADepartment of Lymphoma/Myeloma, MD Anderson Cancer Center, Houston, TXDepartment of Hematologic Oncology and Blood Disorders, Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, NCDivision of Bone Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, CADepartment of Blood and Marrow Transplantation and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FLDepartment of Hematologic Oncology and Blood Disorders, Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, NCDepartment of Hematology-Oncology, University of Pennsylvania, Philadelphia, PAAbstract: Outcomes of bispecific antibodies in patients with renal impairment (RI) are not well characterized, given the exclusion of these patients from clinical trials. Herein, we evaluated patients with relapsed/refractory multiple myeloma and RI treated with standard-of-care teclistamab. RI was defined as creatinine clearance (CrCl) <40 mL/min. CrCl <30 mL/min or dialysis dependence was defined as severe RI. Of the 384 included patients, 81 (21%) had RI, including 45 (18%) with severe RI, and 18 (5%) on dialysis. Patients with RI were more likely to be older (median age, 71 vs 67 years; P = .002) and have a higher median number of previous lines of therapy (7 vs 6; P = .04). Rates and severity of cytokine release syndrome (51% vs 59%; grade ≥3: 1.2% vs 1%) and immune effector cell–associated neurotoxicity syndrome (16% vs 13%; grade ≥3: 2.5% vs 2.6%) were similar in patients with and without RI, respectively. Patients with RI had higher baseline and day 30 post-teclistamab grade ≥3 anemia and grade ≥3 thrombocytopenia. Renal function did not worsen after teclistamab initiation in most patients with RI outside of the context of disease progression. Overall response rate (52% vs 56%; P = .61) and survival outcomes (median progression-free survival, 4.6 vs 6.5 months; P = .62) were comparable in patients with and without RI, respectively, after a median follow-up of 9.9 months. No differences in overall survival or non-relapse mortality were noted. Our findings suggest that treatment with teclistamab is feasible in patients with RI, including those on dialysis, with a similar safety and efficacy profile to patients without RI.http://www.sciencedirect.com/science/article/pii/S2473952925002113 |
| spellingShingle | Danai Dima Aimaz Afrough Utkarsh Goel Ariel F. Grajales-Cruz Jack Khouri Kelley Julian Oren Pasvolsky Rahul Banerjee Beatrice Razzo Christopher J. Ferreri Mariola A. Vazquez-Martinez James A. Davis Aishwarya Sannareddy Omar Castaneda Shahzad Raza Andrew J. Portuguese Mahmoud R. Gaballa Masooma S. Rana Alex Lieberman-Cribbin Shaun DeJarnette Rebecca Gonzalez Anna Chen Megan M. Herr Lekha Mikkilineni Hitomi Hosoya Evguenia Ouchveridze Gurbakhash Kaur Adriana Rossi Leyla Shune Faiz Anwer Yi Lin Shambavi Richard Douglas W. Sborov Rachid C. Baz Alfred L. Garfall Hans C. Lee Larry D. Anderson, Jr. Andrew J. Cowan Krina K. Patel Peter M. Voorhees Surbhi Sidana Doris K. Hansen Shebli Atrash Sandra P. Susanibar-Adaniya Teclistamab for patients with heavily pretreated relapsed/refractory multiple myeloma and renal impairment Blood Advances |
| title | Teclistamab for patients with heavily pretreated relapsed/refractory multiple myeloma and renal impairment |
| title_full | Teclistamab for patients with heavily pretreated relapsed/refractory multiple myeloma and renal impairment |
| title_fullStr | Teclistamab for patients with heavily pretreated relapsed/refractory multiple myeloma and renal impairment |
| title_full_unstemmed | Teclistamab for patients with heavily pretreated relapsed/refractory multiple myeloma and renal impairment |
| title_short | Teclistamab for patients with heavily pretreated relapsed/refractory multiple myeloma and renal impairment |
| title_sort | teclistamab for patients with heavily pretreated relapsed refractory multiple myeloma and renal impairment |
| url | http://www.sciencedirect.com/science/article/pii/S2473952925002113 |
| work_keys_str_mv | AT danaidima teclistamabforpatientswithheavilypretreatedrelapsedrefractorymultiplemyelomaandrenalimpairment AT aimazafrough teclistamabforpatientswithheavilypretreatedrelapsedrefractorymultiplemyelomaandrenalimpairment AT utkarshgoel teclistamabforpatientswithheavilypretreatedrelapsedrefractorymultiplemyelomaandrenalimpairment AT arielfgrajalescruz teclistamabforpatientswithheavilypretreatedrelapsedrefractorymultiplemyelomaandrenalimpairment AT jackkhouri teclistamabforpatientswithheavilypretreatedrelapsedrefractorymultiplemyelomaandrenalimpairment AT kelleyjulian teclistamabforpatientswithheavilypretreatedrelapsedrefractorymultiplemyelomaandrenalimpairment AT orenpasvolsky teclistamabforpatientswithheavilypretreatedrelapsedrefractorymultiplemyelomaandrenalimpairment AT rahulbanerjee teclistamabforpatientswithheavilypretreatedrelapsedrefractorymultiplemyelomaandrenalimpairment AT beatricerazzo teclistamabforpatientswithheavilypretreatedrelapsedrefractorymultiplemyelomaandrenalimpairment AT christopherjferreri teclistamabforpatientswithheavilypretreatedrelapsedrefractorymultiplemyelomaandrenalimpairment AT mariolaavazquezmartinez teclistamabforpatientswithheavilypretreatedrelapsedrefractorymultiplemyelomaandrenalimpairment AT jamesadavis teclistamabforpatientswithheavilypretreatedrelapsedrefractorymultiplemyelomaandrenalimpairment AT aishwaryasannareddy teclistamabforpatientswithheavilypretreatedrelapsedrefractorymultiplemyelomaandrenalimpairment AT omarcastaneda teclistamabforpatientswithheavilypretreatedrelapsedrefractorymultiplemyelomaandrenalimpairment AT shahzadraza teclistamabforpatientswithheavilypretreatedrelapsedrefractorymultiplemyelomaandrenalimpairment AT andrewjportuguese teclistamabforpatientswithheavilypretreatedrelapsedrefractorymultiplemyelomaandrenalimpairment AT mahmoudrgaballa teclistamabforpatientswithheavilypretreatedrelapsedrefractorymultiplemyelomaandrenalimpairment AT masoomasrana teclistamabforpatientswithheavilypretreatedrelapsedrefractorymultiplemyelomaandrenalimpairment AT alexliebermancribbin teclistamabforpatientswithheavilypretreatedrelapsedrefractorymultiplemyelomaandrenalimpairment AT shaundejarnette teclistamabforpatientswithheavilypretreatedrelapsedrefractorymultiplemyelomaandrenalimpairment AT rebeccagonzalez teclistamabforpatientswithheavilypretreatedrelapsedrefractorymultiplemyelomaandrenalimpairment AT annachen teclistamabforpatientswithheavilypretreatedrelapsedrefractorymultiplemyelomaandrenalimpairment AT meganmherr teclistamabforpatientswithheavilypretreatedrelapsedrefractorymultiplemyelomaandrenalimpairment AT lekhamikkilineni teclistamabforpatientswithheavilypretreatedrelapsedrefractorymultiplemyelomaandrenalimpairment AT hitomihosoya teclistamabforpatientswithheavilypretreatedrelapsedrefractorymultiplemyelomaandrenalimpairment AT evgueniaouchveridze teclistamabforpatientswithheavilypretreatedrelapsedrefractorymultiplemyelomaandrenalimpairment AT gurbakhashkaur teclistamabforpatientswithheavilypretreatedrelapsedrefractorymultiplemyelomaandrenalimpairment AT adrianarossi teclistamabforpatientswithheavilypretreatedrelapsedrefractorymultiplemyelomaandrenalimpairment AT leylashune teclistamabforpatientswithheavilypretreatedrelapsedrefractorymultiplemyelomaandrenalimpairment AT faizanwer teclistamabforpatientswithheavilypretreatedrelapsedrefractorymultiplemyelomaandrenalimpairment AT yilin teclistamabforpatientswithheavilypretreatedrelapsedrefractorymultiplemyelomaandrenalimpairment AT shambavirichard teclistamabforpatientswithheavilypretreatedrelapsedrefractorymultiplemyelomaandrenalimpairment AT douglaswsborov teclistamabforpatientswithheavilypretreatedrelapsedrefractorymultiplemyelomaandrenalimpairment AT rachidcbaz teclistamabforpatientswithheavilypretreatedrelapsedrefractorymultiplemyelomaandrenalimpairment AT alfredlgarfall teclistamabforpatientswithheavilypretreatedrelapsedrefractorymultiplemyelomaandrenalimpairment AT hansclee teclistamabforpatientswithheavilypretreatedrelapsedrefractorymultiplemyelomaandrenalimpairment AT larrydandersonjr teclistamabforpatientswithheavilypretreatedrelapsedrefractorymultiplemyelomaandrenalimpairment AT andrewjcowan teclistamabforpatientswithheavilypretreatedrelapsedrefractorymultiplemyelomaandrenalimpairment AT krinakpatel teclistamabforpatientswithheavilypretreatedrelapsedrefractorymultiplemyelomaandrenalimpairment AT petermvoorhees teclistamabforpatientswithheavilypretreatedrelapsedrefractorymultiplemyelomaandrenalimpairment AT surbhisidana teclistamabforpatientswithheavilypretreatedrelapsedrefractorymultiplemyelomaandrenalimpairment AT doriskhansen teclistamabforpatientswithheavilypretreatedrelapsedrefractorymultiplemyelomaandrenalimpairment AT shebliatrash teclistamabforpatientswithheavilypretreatedrelapsedrefractorymultiplemyelomaandrenalimpairment AT sandrapsusanibaradaniya teclistamabforpatientswithheavilypretreatedrelapsedrefractorymultiplemyelomaandrenalimpairment |